Lv1
58 积分 2025-06-24 加入
Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial
11小时前
已完结
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
16天前
已完结
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
16天前
已完结
Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial
28天前
已完结
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
28天前
已完结
Mazdutide versus placebo in Chinese adults with type 2 diabetes
28天前
已完结
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
1个月前
已完结
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
3个月前
已完结
Mazdutide versus placebo in Chinese adults with type 2 diabetes
3个月前
已完结
Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism
3个月前
已完结
皖公网安备34019202002308
